Article

Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.

Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.

Read the full story:

http://hcp.lv/KahW6a

Source: Reuters

Related Videos
John Barkett, MBA
John Barkett, MBA
CK Wang, MD, COTA
John Barkett, MBA
Tom Belmont
Pieter Sonneveld, MD, PhD
Related Content
Through data from genome-wide association studies, the researchers identified several single nucleotide polymorphisms contributing to the causal relationship between insomnia and atopic dermatitis. | Image credit: amenic181 - stock.adobe.com
May 31st 2025

Study Explores Link Between Insomnia, Atopic Dermatitis

AJMC Contributor
Researchers found a causal association between insomnia and atopic dermatitis and identified several genetic variations contributing to the association.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
The connection between anemia and mortality among patients with RA could likely be explained by inflammation, explained the researchers. | Image credit: Matthieu - stock.adobe.com
May 30th 2025

Anemia Linked With Higher Risk of All-Cause, CVD-Related Mortality in Rheumatoid Arthritis

AJMC Contributor
Iron deficiency anemia increased the risk of death from any cause, while non-iron deficiency anemia was linked with an increased risk of cardiovascular disease (CVD)-related death in rheumatoid arthritis.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
While significant progress has been made, innovations in vector design, immune modulation, and delivery strategies are needed to further improve gene therapy for DMD. | Image credit: RFBSIP - stock.adobe.com
May 30th 2025

Hurdles Remain Despite Progress in Gene Therapy for DMD

Rose McNulty
Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.
vials of insulin | Image credit: Sherry Young - stock.adobe.com
May 30th 2025

AI Matches Physician Accuracy in Insulin Dosing for T2D

Laura Joszt, MA
Artificial intelligence (AI) can enhance insulin dosing accuracy for hospitalized patients with type 2 diabetes (T2D), improving glycemic control and streamlining physician workflows.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo